Jenna Payesko

Patients with moderate-to-severe nail psoriasis treated with secukinumab experienced significant improvement in the Nail Psoriasis Severity Index.

Baby boomers found to have a relatively high rate of drug abuse compared with other generations.

Lofexidine treats symptoms associated with opioid withdrawal and supports discontinuation of opioids.

New Drug Applications filed for halobetasol propionate and tazarotene lotion, a topical treatment for plaque psoriasis.

Fingolimod shows 82% efficacy reducing the annualized multiple sclerosis relapse rate.

Elagolix is an orally administered gonadotropin-releasing hormone or GnRH antagonist for endometriosis with associated pain.

Once-daily HIV treatment found to be highly effective and well-tolerated in treating antiretroviral-naïve HIV-1 patients.

Trials will evaluate the efficacy of brexpiprazole in patients with bipolar I disorder who experience an acute manic episode, with or without mixed features, requiring hospitalization.

Calcipotriene and betamethasone dipropionate treats mild to moderate plaque psoriasis in adult patients.

QuickShot Testosterone (Xyosted) application rejected due to deficiencies related to clinical data.

Ustekinumab (Stelara) treats moderate to severe plaque psoriasis in adolescents who are candidates for phototherapy or systemic therapy.

The novel drug, intepirdine, was under investigation to treat patients with mild to moderate Alzheimer’s disease who were receiving donepezil therapy.